Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP262529.RA856ZzCKVelNJCokuYea9Hy_m60NkenNQ5SWitSwXxxw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP262529.RA856ZzCKVelNJCokuYea9Hy_m60NkenNQ5SWitSwXxxw130_assertion type Assertion NP262529.RA856ZzCKVelNJCokuYea9Hy_m60NkenNQ5SWitSwXxxw130_head.
- NP262529.RA856ZzCKVelNJCokuYea9Hy_m60NkenNQ5SWitSwXxxw130_assertion description "[Thus, we have shown that rosiglitazone appears to have direct anti-atherosclerotic effects in an animal model of diabetes-associated atherosclerosis which are at least partly due to effects on VCAM-1, ICAM-1, MCP-1 and P-selectin expression which leads to decreased leukocyte adhesion and macrophage infiltration.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP262529.RA856ZzCKVelNJCokuYea9Hy_m60NkenNQ5SWitSwXxxw130_provenance.
- NP262529.RA856ZzCKVelNJCokuYea9Hy_m60NkenNQ5SWitSwXxxw130_assertion evidence source_evidence_literature NP262529.RA856ZzCKVelNJCokuYea9Hy_m60NkenNQ5SWitSwXxxw130_provenance.
- NP262529.RA856ZzCKVelNJCokuYea9Hy_m60NkenNQ5SWitSwXxxw130_assertion SIO_000772 18093596 NP262529.RA856ZzCKVelNJCokuYea9Hy_m60NkenNQ5SWitSwXxxw130_provenance.
- NP262529.RA856ZzCKVelNJCokuYea9Hy_m60NkenNQ5SWitSwXxxw130_assertion wasDerivedFrom befree-20140225 NP262529.RA856ZzCKVelNJCokuYea9Hy_m60NkenNQ5SWitSwXxxw130_provenance.
- NP262529.RA856ZzCKVelNJCokuYea9Hy_m60NkenNQ5SWitSwXxxw130_assertion wasGeneratedBy ECO_0000203 NP262529.RA856ZzCKVelNJCokuYea9Hy_m60NkenNQ5SWitSwXxxw130_provenance.